Actinium Pharma (ATNM) Announces Actimab-A Program Data Selected for ASH Presentation
- DuPont (DD) Tops Q4 EPS by 9c; Sees Merger Closing in First Half
- Alibaba (BABA) Tops Q3 EPS by 17c, Revenues Rise 54%
- Barclays Downgrades Apple (AAPL) to Equalweight, Concerned India/China Will not Emerge As Growth Catalysts
- Yahoo! (YHOO) Tops Q4 EPS by 4c; Sees Verizon Deal Closing in Q2, Not Q1
- SAP (SAP) Q4 IFRS Revenues Rises 7%, Boosts 2020 Outlook
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced that data from the Company’s Actimab-A program, Actinium's most advanced alpha particle immunotherapy program intended for newly diagnosed AML patients over the age of 60, has been selected by the American Society of Hematology (ASH) Program Committee for poster presentation at the 58th Annual Meeting in San Diego, California on December 5, 2016.
Title: Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Location: San Diego Convention Center, Hall GH
Presentation: December 5, 6:00 PM - 8:00 PM
Abstracts are expected to be available at www.hematology.org on November 3, 2016 at 9:00 am Eastern time. In addition, the abstracts will be published online in the December 3, 2015 supplemental volume of Blood.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Actinium Announces Participation in Three Upcoming Hematology Events
- Endo Int'l (ENDP) Agrees to Abandon Noncompetitive Pay-for-Delay in Settlement with FTC
- Minerals Technologies (MTX) Elects Matthew Garth as CFO
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!